Stockscreener 앱 받기
1.31
5.07%
-0.07
시간 외 거래:
1.31
전일 마감가:
$1.38
열려 있는:
$1.39
하루 거래량:
100.54K
Relative Volume:
0.17
시가총액:
$56.29M
수익:
-
순이익/손실:
$-40.56M
주가수익비율:
-1.1197
EPS:
-1.17
순현금흐름:
$-35.28M
1주 성능:
+5.65%
1개월 성능:
+37.88%
6개월 성능:
-59.63%
1년 성능:
-65.71%
1일 변동 폭
$1.291
$1.39
1주일 범위
$1.20
$1.401
52주 변동 폭
$0.8505
$4.42
Pds Biotechnology Corporation Stock (PDSB) Company Profile
명칭
Pds Biotechnology Corporation
전화
800-208-3343
주소
303A COLLEGE ROAD EAST, PRINCETON
PDSB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.31 | 56.29M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-01 | 개시 | B. Riley Securities | Buy |
| 2021-06-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 개시 | Alliance Global Partners | Buy |
| 2020-03-09 | 개시 | Noble Capital Markets | Outperform |
| 2019-10-24 | 개시 | Chardan Capital Markets | Buy |
모두보기
Pds Biotechnology Corporation 주식(PDSB)의 최신 뉴스
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN
PDS Biotechnology Enters $20M Securities Purchase Agreement - TipRanks
B. Riley Adjusts Price Target on PDS Biotechnology to $5 From $7, Maintains Buy Rating - marketscreener.com
B. Riley Expects Stronger Earnings for PDS Biotechnology - Defense World
PDS Biotechnology Director Sir Richard Sykes Retires - TipRanks
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
PDS Biotechnology Corporation Announces Three Abstracts Accepted for ASCO 2025 on Versamune® HPV Immunotherapy - Nasdaq
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
Raymond James Financial Inc. Takes Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Pds Biotech Announces Pds01adc Clinical Data To Be Presented At The American Association For Cancer Research - MarketScreener
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Globe and Mail
Blair William & Co. IL Purchases 35,757 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDSB stock touches 52-week low at $1.12 amid market challenges - Investing.com
Virtu Financial LLC Takes $89,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish - Asianet Newsable
HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price - Defense World
H.C. Wainwright cuts PDS Biotechnology stock target to $13 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts PDS Biotechnology stock target to $13 - Investing.com India
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
PDS Biotechnology Advances Cancer Immunotherapy Trials - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy By Investing.com - Investing.com South Africa
PDS Biotech commences phase 3 trial for HPV cancer therapy - Investing.com
PDS Biotech Advances Cancer Immunotherapy with New Clinical Trial - TipRanks
Earnings call transcript: PDS Biotech Q4 2024 shows narrowed loss, stock rises - Investing.com
PDS Biotechnology Corp reports results for the quarter ended December 31Earnings Summary - TradingView
PDS BIOTECHNOLOGY Earnings Results: $PDSB Reports Quarterly Earnings - Nasdaq
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update - MarketScreener
A Look at PDS Biotechnology's Upcoming Earnings ReportPDS Biotechnology (NASDAQ:PDSB) - Benzinga
PDS Biotechnology Corp expected to post a loss of 28 cents a shareEarnings Preview - TradingView
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference - The Manila Times
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts - Insider Monkey
10 Penny Stocks With Huge Upside Potential According To Analysts - Insider Monkey
PDS Biotechnology (PDSB) Expected to Announce Quarterly Earnings on Wednesday - Defense World
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results - The Manila Times
PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright - Defense World
PDS Biotechnology at Life Sciences Virtual Investor Conference: Strategic Advances in Cancer Treatment - Investing.com Australia
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - Morningstar
PDS Biotech receives FDA clearance to start clinical study on new treatment for metastatic colorectal cancer - Marketscreener.com
Pds Biotechnology Corporation (PDSB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):